
    
      In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve
      good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of
      pemetrexed. So we design the trial to investigate curative effect between
      Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild
      NSCLC.
    
  